Recurrent Head and Neck Squamous Cell Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03522584Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTreatment